Literature DB >> 8612720

Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions.

V V Tertov1, G Bittolo-Bon, I A Sobenin, G Cazzolato, A N Orekhov, P Avogaro.   

Abstract

Previous studies demonstrated that more electronegative low density lipoprotein (LDL) isolated from human blood by ion exchange chromatography has a chemical composition and physical properties similar to desialylated LDL obtained by lectin chromatography (Avogaro et al., 1988; Orekhov et al., 1989). In this study, sialic acid content and percentage of desialylated LDL in the electronegative LDL (LDL-) subfraction have been investigated. The sialic acid content of the LDL- was 2- to 6-fold lower than that of native LDL and close to that of desialylated LDL. In the native LDL subfraction, 83% of lipoprotein particles did not bind to the Ricinus communis agglutinin, indicating lack of terminal galactose, presumably appearing as a result of desialylation of LDL carbohydrate chains. By contrast, a major proportion of human LDL- (81%) was bound to the lectin. It was also found that the desialylated LDL subfraction consists of 88% LDL-. Native LDL did not affect the contents of free and esterified cholesterol in intimal cells cultured from grossly normal human aorta, while LDL- and desialylated LDL induced a 1.5- to 3-fold increase in the intracellular content of cholesteryl esters. Thus, LDL- is desialylated LDL which induces lipid accumulation in intimal cells. Our findings suggest that the LDL- particle is similar if not identical to the desialylated LDL particle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8612720     DOI: 10.1006/exmp.1995.1018

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  8 in total

1.  The content of lipoperoxidation products in normal and atherosclerotic human aorta.

Authors:  V V Tertov; V V Kaplun; I A Mikhailova; I V Suprun; A N Orekhov
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

Review 2.  LDL electronegativity index: a potential novel index for predicting cardiovascular disease.

Authors:  Ekaterina A Ivanova; Yuri V Bobryshev; Alexander N Orekhov
Journal:  Vasc Health Risk Manag       Date:  2015-08-28

3.  Macrophages in immunopathology of atherosclerosis: a target for diagnostics and therapy.

Authors:  Alexander N Orekhov; Igor A Sobenin; Mikhail A Gavrilin; Alexei Gratchev; Svetlana Y Kotyashova; Nikita G Nikiforov; Julia Kzhyshkowska
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 4.  Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.

Authors:  Ekaterina A Ivanova; Veronika A Myasoedova; Alexandra A Melnichenko; Andrey V Grechko; Alexander N Orekhov
Journal:  Oxid Med Cell Longev       Date:  2017-05-07       Impact factor: 6.543

Review 5.  Electronegative LDL: a circulating modified LDL with a role in inflammation.

Authors:  Montserrat Estruch; José Luis Sánchez-Quesada; Jordi Ordóñez Llanos; Sònia Benítez
Journal:  Mediators Inflamm       Date:  2013-08-22       Impact factor: 4.711

6.  Approach to reduction of blood atherogenicity.

Authors:  Alexander N Orekhov; Alexandra A Melnichenko; Igor A Sobenin
Journal:  Oxid Med Cell Longev       Date:  2014-06-29       Impact factor: 6.543

Review 7.  Modified low density lipoprotein and lipoprotein-containing circulating immune complexes as diagnostic and prognostic biomarkers of atherosclerosis and type 1 diabetes macrovascular disease.

Authors:  Alexander N Orekhov; Yuri V Bobryshev; Igor A Sobenin; Alexandra A Melnichenko; Dimitry A Chistiakov
Journal:  Int J Mol Sci       Date:  2014-07-21       Impact factor: 5.923

8.  Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.

Authors:  Gerd Hörl; Harald Froehlich; Ulrika Ferstl; Gerhard Ledinski; Josepha Binder; Gerhard Cvirn; Tatjana Stojakovic; Michael Trauner; Christoph Koidl; Erwin Tafeit; Karin Amrein; Hubert Scharnagl; Günther Jürgens; Seth Hallström
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.